Drugs / ENALAPRILAT ANHYDROUS
ENALAPRILAT ANHYDROUS
also known as
enalaprilat · Enalapril diacid dihydrate · Enalapril diacid dihydrate anhydrous · Enalaprilat dihydrate · Enalaprilate · MK-422 · NSC-760053 · Vasotec i.v.
Small molecule targets ACE
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VASOTEC | — | 1988-02-09 | fda.gov ↗ |
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05259137 | Aug 2024 → Aug 2026 | reactive cutaneous fibrous lesion | Nova Scotia Health Authority | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00741156 | Jul 2008 → Jan 2010 | dilated cardiomyopathy, hypertensive disorder | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04640571 | Apr → Nov 2021 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 4 | NCT02639637 | Dec 2015 → Jun 2017 | type 2 diabetes mellitus | Vanderbilt University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01413542 Comparator | Nov 2011 → Jul 2013 | hypertensive disorder, type 2 diabetes mellitus | Vanderbilt University | Completed | No outcome recorded |
| — | NCT00226096 Background | Nov 2005 → Sep 2007 | intracerebral hemorrhage | The George Institute | Completed | No outcome recorded |
| — | NCT00248807 Comparator | Oct 2005 → May 2009 | orthostatic hypotension, spinal cord injury | VA Office of Research and Development | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENALAPRILAT ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL577 ↗ |
| Known as | Enalapril diacid dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL577 ↗ |
| Known as | Enalapril diacid dihydrate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL577 ↗ |
| Known as | enalaprilat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01413542 ↗ |
| Known as | Enalaprilat dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL577 ↗ |
| Known as | Enalaprilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL577 ↗ |
| Known as | MK-422 | ChEMBL registry synonym — accepted as the source's own label CHEMBL577 ↗ |
| Known as | NSC-760053 | ChEMBL registry synonym — accepted as the source's own label CHEMBL577 ↗ |
| Known as | Vasotec i.v. | ChEMBL registry synonym — accepted as the source's own label CHEMBL577 ↗ |
| Action | Inhibit | “an angiotensin converting enzyme (ACE) inhibitor given to lower blood pressure (BP)” NCT00248807 ↗ |
| Modality | Small molecule | — CHEMBL577 ↗ |
| Route | Intravenous | “1.25 mg enalaprilat IV” NCT00248807 ↗ |
| Target | ACE | “angiotensin-converting enzyme (ACE) inhibition” PMID 18850311 ↗ Oct 2008 |